{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.2","upperLimit":"82.7","value":"67"},{"groupId":"OG001","lowerLimit":"9.9","upperLimit":"81.6","value":"43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"BV as frontline monotherapy in patients with cHL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Part E"},{"description":"BV as frontline monotherapy in patients with CD30-expressing PTCL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Part F"}],"paramType":"NUMBER","populationDescription":"All subjects who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to 31 months","title":"ORR According to Lugano Criteria Per BICR (Parts E and F)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}